Intelligence Profile
Safety Profile
The safety profile of PT-141 (bremelanotide) is based on limited clinical trial data, primarily from studies in premenopausal women with hypoactive sexual desire disorder. Evidence regarding long-term safety, drug interactions, and use in diverse populations remains thin.
Known Side Effects
Based on completed Phase 2 and Phase 3 clinical trials in premenopausal women, the most commonly reported side effects include:
- Nausea and vomiting
- Flushing
- Headache
- Injection site reactions
- Fatigue
The available literature suggests these effects are generally transient and dose-dependent, though comprehensive safety data across different dosing regimens and administration routes is limited.
Contraindications and Precautions
Evidence for specific contraindications is sparse. Based on the mechanism of action as a melanocortin receptor agonist, theoretical concerns may include:
- Cardiovascular conditions (due to potential effects on blood pressure)
- Pregnancy and breastfeeding (insufficient safety data)
- Severe hepatic or renal impairment (limited pharmacokinetic data)
Drug Interactions
No specific drug interaction studies are documented in the available evidence. Given PT-141's action on melanocortin receptors and potential cardiovascular effects, caution may be warranted with:
- Antihypertensive medications
- Other vasoactive substances
However, this represents theoretical concern rather than established evidence.
Populations That Should Avoid Use
Evidence is extremely limited regarding safety in specific populations. Based on available clinical trial data, the following groups have insufficient safety information:
- Men (limited clinical evidence)
- Postmenopausal women
- Pregnant or breastfeeding women
- Pediatric populations
- Elderly patients
- Patients with significant cardiovascular disease
Evidence Limitations
The safety profile is primarily derived from short-term clinical trials in a narrow population (premenopausal women). Long-term safety data, comprehensive drug interaction profiles, and safety in diverse patient populations require further investigation.
This information is for educational purposes only and should not replace professional medical advice. Consult with a healthcare provider before considering any treatment.